We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Israeli biotech company Enzymotec and Korean pharmaceuticals manufacturer Il Dong have signed an agreement to launch a treatment for cardiovascular disease (CVD) in the Korean market.
Alnylam Pharmaceuticals, a Massachusetts-based therapeutics company, and Canadian drugmaker Inex Pharmaceuticals have announced that the companies are accelerating their collaboration focused on RNAi therapeutics.
Swiss drugmakers Roche and Actelion announced that they have entered into an exclusive worldwide collaboration to jointly develop and commercialize Actelion's selective S1P1 receptor agonist, an immunomodulator with the potential for once-a-day oral dosing.
India-based Ranbaxy Laboratories has announced that Nihon Pharmaceutical Industry, a joint venture between Ranbaxy and Japanese company Nippon Chemiphar, has successfully launched Clarithromycin 50-mg and 200-mg tablets and Terbinafine 125-mg tablets in Japan.
Giant pharmaceuticals group CAPS Holdings Limited shareholders approved the waiver of the company's pre-emptive rights to acquire Shreya Life Sciences stake in the former joint venture entity, CAPS Shreya, at their annual general meeting recently.
Genepharm Australasia Limited has completed the acquisition of Douglas Pharmaceuticals Australia Limited and also completed its associated $60 million fund raising.
Synova Healthcare, Inc., a subsidiary of Synova Healthcare Group, Inc., has entered into an exclusive distribution agreement with QuantRx Biomedical Corporation, a medical technology company with products targeting worldwide health needs.
Merck & Co.'s president of its U.S. human health division, Brad Sheares, is leaving the company after nearly 20 years, the drug maker confirmed Thursday, in what could be a sign of a management shake up.
Roxane Laboratories, Inc., announced that it is conducting a nationwide voluntary recall of a single manufacturing lot of Azathioprine tablets, USP 50 mg, (NDC 00054-4084-25, Lot 558470A, Exp Mar 2009).